CD2用于预防头颈部肿瘤患者口腔黏膜炎的多中心随机研究。

CD2 for Prevention of Oral Mucositis in Patients With Head and Neck Tumors: A Multicentric Randomized Study.

作者信息

DE Sanctis Vitaliana, Belgioia Liliana, Cante Domenico, LA Porta Maria R, Caspiani Orietta, Guarnaccia Roberta, Argenone Angela, Muto Paolo, Musio Daniela, DE Felice Francesca, Maurizi Francesca, Bunkhelia Feisal, Ruo Redda Maria Grazia, Reali Alessia, Valeriani Maurizio, Osti Mattia F, Alterio Daniela, Bacigalupo Almalina, Russi Elvio G

机构信息

Department of Medicine and Surgery and Translational Medicine, Radiation Oncology, S. Andrea Hospital, Sapienza University of Rome, Rome, Italy

Radiation Oncology, Policlinico San Martino and University, Genoa, Italy.

出版信息

Anticancer Res. 2019 Apr;39(4):1935-1942. doi: 10.21873/anticanres.13303.

DOI:10.21873/anticanres.13303

PMID:30952736

Abstract

BACKGROUND

Oropharyngeal mucositis occurs in virtually all patients with head and neck cancer receiving radiochemotherapy. The manipulation of the oral cavity microbiota represents an intriguing and challenging target.

PATIENTS AND METHODS

A total of 75 patients were enrolled to receive Lactobacillus brevis CD2 lozenges or oral care regimen with sodium bicarbonate mouthwashes. The primary endpoint was the incidence of grade 3 or 4 oropharyngeal mucositis during radiotherapy treatment.

RESULTS

There was no statistical difference in the incidence of grade 3-4 oropharyngeal mucositis between the intervention and control groups (40.6% vs. 41.6% respectively, p=0.974). The incidence of pain, dysphagia, body weight loss and quality of life were not different between the experimental and standard arm.

CONCLUSION

Our study was not able to demonstrate the efficacy of L. brevis CD2 lozenges in preventing radiation-induced mucositis in patients with head and neck cancer. Although modulating homeostasis of the salivary microbiota in the oral cavity seems attractive, it clearly needs further study.

摘要